Personalized therapy for pazopanib by pharmacokinetic analysis in patients with renal cell carcinoma or malignant soft tissue tumor

Personalized therapy for pazopanib by pharmacokinetic analysis in patients with renal cell carcinoma or malignant soft tissue tumor - Personalized therapy for pazopanib by PK analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034034

Enrollment

Registered

2018-09-05

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma Malignant soft tissue tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients receiving pazopanib for renal cell carcinoma or malignant soft tissue tumor 2)Witten informed concent from patients or proxies

Exclusion criteria

Exclusion criteria: 1)History of hypersensitivity to pazopanib 2)Pregnant status 3)Lactation status

Design outcomes

Primary

Measure	Time frame
To analyze blood concentrations of pazopanib showing side effects and efficacy	—

Secondary

Measure	Time frame
To examine factors that affect the blood concentration of pazopanib	—

Countries

Japan

Contacts

Public ContactJun Ito

Tohoku Medical and Pharmaceutical University Faculty of Medicine Department of urology

itojun@tohoku-mpu.ac.jp022-234-4181

Outcome results